GENinCode UK Ltd. ( (GB:GENI) ) just unveiled an announcement.
GENinCode Plc has announced the approval of a grant of options over 14,028,305 new ordinary shares under its 2021 Share Option Plan, representing 4.89% of the company’s existing issued share capital. This initiative aims to retain and incentivize staff, rewarding them for achieving long-term objectives. The options, exercisable at 3.7 pence per share, are set to vest on the second anniversary of the grant date and have a 10-year term. This move is expected to strengthen GENinCode’s ability to maintain a motivated workforce, potentially enhancing its market position in the genetic risk assessment industry.
More about GENinCode UK Ltd.
GENinCode Plc is a UK-based company specializing in genetic risk assessment for cardiovascular disease, which is the leading cause of death and disability worldwide. The company operates in the UK, Europe, and the United States, providing predictive technology for preventative care and treatment strategies through in vitro diagnostic molecular tests.
YTD Price Performance: -25.00%
Average Trading Volume: 725,572
Technical Sentiment Signal: Buy
Current Market Cap: £8.18M
For an in-depth examination of GENI stock, go to TipRanks’ Stock Analysis page.